Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease

Cardiovascular Drugs and Therapy

Volumn 10, Issue SUPPL. 2, 1996, Pages 639-647

  Ferrari, R ^a   Ceconi, C ^a   Curello, S ^a   Pepi, P ^a   Mazzoletti, A ^a   Visioli, O ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Angiotensin converting enzyme; Captopril; Cardiac protection; Coronary artery disease; Enalapril; Quinapril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; BLOOD PRESSURE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE COURSE; ENZYME ACTIVITY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SYMPTOM; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; BLOOD PRESSURE; CLINICAL TRIALS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; VENTRICULAR FUNCTION, LEFT;

EID: 0030449640     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00052511     Document Type: Conference Paper

References (132)

1. Dzau V, Braunwald E, et al. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991;121:1244-1203.
2. Dzau VJ. Angiotensin-converting enzyme as a multimechanistic factor in CAD. J Myocard Ischemia 1995;7(Suppl. 1):6-14.
3. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984;144:1947-1953.
4. Zusman RM. Renin- and non-renin-mediated antihypertensive actions of converting-enzyme inhibitors. Kidney Int 1984;25:969-983.
5. Tewksbury DA. Angiotensinogen: Biochemistry and molecular biology. In: Laragh JH, Bremer BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1990:1197-1216.
6. The CONSENSUS Trial Group. Effect of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325: 293-302.
8. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
10. Pfeffer MA, Lasmas GA, Vaughn DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988;319:80-86.
11. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting enzyme inhibition. Lancet 1991;337:872-876.
12. Lonn EM, Yusuf S, Jha P. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2068.
13. Admiraal PJJ, Derkx FHM, Danser J, et al. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 1990;15: 44-45
14. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993;153: 937-942.
15. Paul M, Schunkert H, Allen P, et al. Widespread distribution of angiotensin converting enzyme mRNA in human tissues. J Hypertens 1990;8(Suppl. 3):S36.
16. Okamura T, Miyazaki M, Ingami T, et al. Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension 1986;8:560-565.
17. Schunkert H, Dzau VJ, Tang SS, et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility and relaxation. J Clin Invest 1990;86:1913-1920.
18. Hirsch AT, Talsness CE, Schunkert H, et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69: 475-482.
19. Baumgarten CR, Linz W, Kunkel G, et al. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993;108:293-295.
20. Campbell DJ, Kladis A, Duncan AM. Bradykinin peptides in kidney, blood and other tissues of the rat. Hypertension 1993;21:155-165.
21. Ferrari R, Anand IS. Neurohumoral changes in untreated heart failure. Cardiovasc Drugs Ther 1989;3:979-986.
22. Ferrari R, Anand IS. Neurohumoral changes in untreated cardiac failure. I: Cortina A, ed. Congestive Cardiac Failure, Pathophysiological Bases and Therapeutic Implications. Oviedo, Spain: Prous Science Publishers, 1992: 49-58.
23. Ferrari R, Ceconi C, de Giuli F, Panzali AF, Harris P. Temporal relations of the endocrine response to hypotension with sodium. Cardioscience 1992;3:51-59.
24. Ferrari R, Rodella A, de Giuli F, Panzali AF, Harris P. Temporal relations of the endocrine response to exercise. Cardioscience 1991;2:131-139.
25. Ferrari R, Ceconi C, Rodella A, Harris P, Visioli O. Hormonal response in untreated myocardial infarction. Cardioscience 1989;1:55-60.
26. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
27. Dzau VJ. Angiotensin converting enzyme inhibitors and the cardiovascular system. J Hypertens 1992;10(Suppl. 3): S3-S10.
28. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin converting enzyme inhibitor. Circulation 1982;66:1249-1255.
29. Lefer AM, Peck RC. Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacology 1984;29:61-69.
30. Sweet CS. Issues surrounding a local cardiac renin system and the beneficial actions of angiotensin-converting enzyme inhibitors in ischemic myocardium. Am J Cardiol 1990;65:111-113.
31. Liang C, Gavras I, Black J, Sherman LG, Hood WB. Renin-angiotensin enzyme inhibitors in acute myocardial infarction in dogs. Circulation 1982;66:1249-1255.
32. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ. Effect of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-1047.
33. Westlin W, Mullane K. Does captopril attenuate reperfusion induced myocardial dysfunction by scavenging free radicals? (abstr) Circulation 1988;77(Suppl. I):130.
34. Przyklenk K, Kloner RA. Acute effects of hydralazine and enalapril on contractile function of post-ischemic stunned myocardium. Am J Cardiol 1987;60:934-936.
35. Przyklenk K, Kloner RA. Relationships between structure and effects of ACE inhibitors: Comparative effects in myocardial ischemia/reperfusion injury. Br J Clin Pharmacol 1989;28:167S-175S.
36. Cargnoni A, Boraso A, Scotti C, et al. Effect of angiotensin converting enzyme inhibition with quinaprilat on the ischaemic and reperfused myocardium. J Mol Cell Cardiol 1994;26:69-86.
37. Ferrari R, Cargnoni A, Curello S, Boraso A, Visioli O. Protection of the ischemic myocardium by the converting enzyme inhibitor zofenopril: insight into its mechanism of action. J Cardiovasc Pharmacol 1992;20:694-704.
38. Van Gilst VM, deGraeff PA, Wesseling H, deLangen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril and HOE498. J Cardiovasc Pharmacol 1986;8:722-728.
39. Linz W, Martorana PA, Scholkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15(Suppl. 6):S99-S109.
40. Kigma JH, de Graeff PA, van Gilst WH, Binsbergen E, de Langen CDJ, Wesseling H. Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in anesthetized pig. Postgrad Med J 1986;62(Suppl. I):159-163.
41. Pi X, Chen X. Captopril and ramiprilat protect against free radical injury in isolated working rat heart. J Mol Cell Cardiol 1989;21:1261-1271.
42. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990;40:2169-2175.
43. Bickerton RK, Buckley JP. Evidence for a central mechanism in angiotensin induced hypertension. Proc Soc Exp Biol Med 1961;106:834-836.
44. Ferrario CM, Gildenberg PL, McCubbin JW. Cardiovascular actions of angiotensin mediated by the central nervous system. Circ Res 1972;30:257-262.
45. Zimmermann BG. Evaluation of peripheral and central components of action of angiotensin on the sympathetic nervous system. J Pharmacol Exp Ther 1967;158:1-10.
46. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. Hypertension 1984;2:581-587.
47. Ziogas J, Story DF, Rand MJ. Effects of locally generated angiotensin II on noradrenergic transmission in guinea pig isolated atria. Eur J Pharmacol 1985;106:11-18.
48. Goldsmith SR, Haskins GJ, Miller E. Angiotensin II and sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 1993;21:1107-1113.
49. Richard DP, Benedict CR, Kronenberg MW, et al. for the SOLVD Investigators. Effect of long-term enalapril on adrenergic activity and sensitivity during exercise in patients with left ventricular dysfunction (abstr). Circulation 1993; 88:1293.
50. Gilbert EM, Sandoval A, Larrabee P, Rentund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation 1993;88:472-480.
51. Ferrari R, Menotti A, Gei P, de Giuli F, Tabaglio A, Anans IS. Hemodynamics and hormonal changes in chronic heart failure: Effect of ACE inhibition. J Cardiovasc Pharmacol 1992;20:S49-S59.
52. Anand IS, Kalra GS, Ferrari R, Wahi PL, Harris P, Poole-Wilson PA. Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. Int J Cardiol 1990;28:341-346.
53. Gavras H, Brown JJ, Lever AF, Macadam RF, Robertson JJS. Acute renal failure, tubular necrosis and myocardial infarction induced into the rabbit by intravenous angiotensin-II. Lancet 1971;122:1382-1388.
54. Krasney JA, Thompson JL, Lowe RF. Cardiac effects of angiotensin injections into perfused right coronary artery. Am J Physiol 1967;213:134-138.
55. Rouleau JL, Chatterjee K, Benge W, Parmley WW, Hiramatsu B. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: A comparative study. Circulation 1982;65:671-678.
56. Chatterjee K, Rouleau JL, Parmley WW. Haemodynamic effects of captopril in chronic heart failure. Br Heart J 1982;47:233-238.
57. Halperin JL, Faxon DP, Creager MA, et al. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. Am J Cardiol 1982;50:967-972.
58. Wenting GJ, Man in't Veld AJ, Woittiez AJ, et al. Acute and chronic heart failure: Correlation with plasma levels of noradrenaline, renin and aldosterone. Br Heart J 1983; 49:65-76.
59. Mattioli G, Ricci S, Rigo R, Roberto R, Fusaro MT, Cappello C. Effects of captopril in heart failure complicating acute myocardial infarction and persistence of acute hemodynamic effect in chronic heart failure after 3 years of treatment. Postgrad Med J 1986;62(Suppl. I): 164-166.
60. Schultheiss HP, Ullrich M, Schindler M, Schulze SK, Strauer BE. The effect of ACE inhibition on myocardial energy metabolism. Eur Heart J 1990;11(Suppl. B): 116-122.
61. Magrini F, Reggiani P, Roberts N, Mezza R, Ciulla M, Zanchetti A. Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. Am J Med 1988;84(Suppl. 3A):55-60.
62. Linz KW, Scholkens BA, Han YF. Beneficial effects of converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol 1986;88(Suppl. 10): S91-S99.
63. van Gust WH, de Graeff PA, Scholtens E, et al. Potentiation of isosorbide dinitrate-induced coronary dilation by captopril. J Cardiovasc Pharmacol 1987;9:254-255.
64. Daly P, Rouleau JL, Cousineau D, Burgess JH. Acute effect of captopril on the coronary circulation of patients with hypertension and angina. Am J Med 1984;76(Suppl. B):111-115.
65. Daly P, Mettauer P, Rouleau JL, Cousineau D, Burgess JH. Lack of reflex increase in myocardial sympathetic tone after captopril: Potential antianginal effect. Circulation 1985;71:317-325.
66. Dzau VJ. Short and long-term determinants of cardiovascular function and therapy. Contributions of circulating and tissue renin-angiotensin systems. J Cardiovasc Pharmacol 1989;14(Suppl. 4):S1-S5.
67. Strozzi C, Portaluppi F, Cocco G, Urso L. Ergometric evaluation of the effects of enalapril maleate in normotensive patients with stable angina. Clin Cardiol 1988;11: 246-249.
68. Strozzi C, Cocco G, Portaluppi F, et al. Effects of captopril on the physical work capacity of normotensive patients with stable effort angina pectoris. Cardiology 1987;74: 226-228.
69. Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton GC, Fox JM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 1989;62:112-117.
70. Bussman WD, Goerke S, Schneider W, Kaltenbach M. Angiotensin-Converting-Enzyme-Hemmer bei Angina Pectoris. Deutsch Med Wochenschr 1988;113:548-550.
71. Cleland JGF, Henderson E, McLenachan JM, Findlay IN, Dargie HJ. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol 1991;17:733-739.
72. Thurmanm P, Odenthal HJ, Rletbrock N. Converting enzyme inhibition in coronary artery disease: A randomized, placebo controlled trial with benazepril. J Cardiovasc Pharmacol 1991;17:718-723.
73. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: The Framingham Study. Ann Intern Med 1970;72:813-822.
74. Kannel WB, Schatzkin A. Sudden death: Lessons from subsets in population studies. J Am Coll Cardiol 1985; 5(Suppl.):141B-149B.
75. Levy D, Garrison MS, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1565.
76. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 1984;53:105-108.
77. Mujais SK, Fouad FM, Tarazi RC. Reversai of left ventricular hypertrophy with captopril: Heterogenicity of response among hypertensive patients. Clin Cardiol 1983;6: 595-602.
78. Dal Palu' C, Pessina AC, Pagman A, et al. Effect of captopril on left ventricular mass and function in hypertensive patients and in the rat. Postgrad Med J 1986;62(Suppl. 1): 85-89.
79. Nakashina Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044-1049.
80. Weber KT, Janicki JS. Angiotensin and the remodelling of the myocardium. Br J Clin Pharmacol 1989;28(Suppl.): 141S-150S.
81. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989;11:1325-1350.
82. Clozel JP, Herd F. Gilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1988;11:568-572.
83. Kromer EP, Riegger GA. Effect of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 1988;62:161-163.
84. Lindpainter K, Ganten D. The cardiac renin-angiotensin system: A synopsis of current experimental and clinical data. Acta Cardiol 1991;46:385-397.
85. Gilendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87:1816-1828.
86. Drexler H, Lindpainter K, Lu W, Schieffer B, Ganteen D. Transient increase in the expression of cardiac angiotensinogen in a rat model of infarction and failure (abstr). Circulation 1989;80(Suppl. II):II459.
87. Bauwens FR, Duprez DA, De Buyzere ML, et al. Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1991;68:925-929.
88. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
89. Luscher TF. Endothelial dysfunction in atherosclerosis. J Myocard Ischem 1995;7(Suppl. 1): 15-20.
90. Luscher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. In: Grobecker H, Heusch G, Strauer BE, eds. Angiotensin and the Heart. Darmstadt: Steinkopff Verlag, 1993.
91. Scicli AG, Carretero OA. Bradykinin-dependent mechanisms contributing to the CV effects of ACE inhibitors. J Myocard Ischem 1995;7(Suppl. 1):21-33.
92. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
93. Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 1990;13:VII43-VII48.
94. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15: S65-S72.
95. Rolland PH, Charpiot P, Friggi A, et al. Effect of angiotensin-converting enzyme inhibition with perindolol on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini pigs. Am J Cardiol 1993;71:22E-27E.
96. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
97. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993;87: 283-290.
98. Michael JB, Plissonier D, Bruneval P. Effect of perindopril on the immune arterial wall remodelling in the rat model of arterial graft rejection. Am J Med 1992;92(Suppl. 4B): 39S-46S.
99. Bilazarian SD, Currier JW, Haudenschild C, et al. Angiotensin converting enzyme inhibition reduces restenosis in experimental angioplasty (abstr.). Circulation 1990; 82(Suppl. II):II297.
100. Rakugi H, Wang DS, Dzau YJ. Potential importance of tissue angiotensin converting enzyme inhibition in preventing neointima formation. Circulation 1994;90: 449-455.
101. The Multicenter European Research Trial with Cilazapril. After angioplasty to prevent transluminal coronary obstruction and restenosis (MERCATOR) Study Group. Does the new angiotensin coverting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR randomized, double blind placebo-controlled trial. Circulation 1992;86:100-110.
102. Naftilan AJ, Pratt RE, Eldrige CS, Lin HL, Dzau VJ. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 1989;13:706-711.
103. Taubman MB, Bradford CB, Isumo S, Tsuda T, Alexander RW, Nedal-Ginard S. Angiotensin II induces c-fos mRNA in aortic smooth muscle. J Biol Chem 1989;264:526-530.
104. Kawahara Y, Sunako M, Tsuda T, Fukuzaki H, Fukumoto Y, Takai Y. Angiotensin-II induces expression of c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 1988;130:52-59.
105. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth-factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
106. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990;8: 565-572.
107. Naftilan AJ, Gilliand GK, Eldrige CS, Kraft AS. Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990;10:5536-5540.
108. Lyall F, Morton JJ, Gillespie D. Angiotensin II stimulates c-jun expression in cultured vascular smooth muscle cells: Superinduction by emetine. Eur J Intern Med 1992;2: 271-273.
109. Scott-Burden T, Resink TJ, Hahn AWA, Buhler FR. Induction of thrombospondin expression in vascular smooth muscle cells by angioten II. J Cardiovasc Pharmacol 1990; 16(Suppl. 7):17-20.
110. Powell JS, Rouge M, Muller RKM, Baumgartner HR. Cilazapril suppresses myointimal proliferation after vascular injury: Effects on growth factor induction and vascular smooth muscle cells. Basic Res Cardiol 1991;86(Suppl. I): 65-74.
111. Powell JS, Muller RKM, Rouge M, Kuhn H, Hefti F. Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1990;16(Suppl. 4): S42-S49.
112. Farber HW, Center DM, Rounds S, Danilov SM. Components of the angiotensin system cause release of neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J 1990;11(Suppl. B):100-107.
113. Shulz PJ, Raij L. Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations. Br J Clin Pharmacol 1989;28:S151-S157.
114. Dohi Y, Hahn AWA, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin-II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992;19:131-137.
115. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-933.
116. Luscher TF, Boulanger CM, Dohi Y, Yang Z. Endothelium-derived contracting factors. Hypertension 1992;19: 117-130.
117. Turlapaty PDMV, Altura BM. Magnesium deficiency produces spasms of the coronary arteries: Relationships to etiology of sudden ischemic heart disease. Science 1980; 208:198-200.
118. Vaughan DE, Shen C, Lazos SA. Angiotensin-II induces secretion of plasminogen activator inhibitor (PAI-1) in vitro (abstr). Circulation 1992;86(Suppl. I):I557.
119. Olson JA Jr, Shiverick KT, Ogilvie S, Buhi WC, Raizada MK. Angiotensin-II induces secretion of plasminogen activator inhibitor I and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Neurobiology 1991;88:1928-1932.
120. Luskutoff DJ, Sawdey M, Mimuro J. Type I plasminogen activator inhibitor. Prog Hemost Thromb 1989;9:87-115.
121. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992;3:285-290.
122. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin-II: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87: 1969-1973.
123. Vaughan DE, Roulleau JL, Premer MA. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995;16:31-36.
124. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
125. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678-684.
126. GISSI Collaborative Group. Oral presentation at the 66th Scientific Sessions of the American Association, November 1993.
127. ISIS Collaborative Group. ISIS-4: Randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Circulation 1993;88:I394.
128. The Chinese Captopril Trial. Oral presentation at the 66th Scientific Sessions of the American Heart Association, November 1993.
129. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
130. Texter M, Lees RS, Pitt B, et al. The Quinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther 1993;7:273-282.
131. Kinoshita A, Urata H, Bumpus FM, et al. Measurement of angiotensin I convering enzyme inhibition in the heart. Circ Res 1993;73:51-60.
132. Pepine CJ, Pitt B, Bertrand ME, Timmis A. Emerging role of ACE inhibitors in vascular protection. J Myocard Ischemia 1995;7(Suppl. 1):50-58.